Case Report: BKV-specific T cells: a fast, safe and potentially effective treatment option for refractory BKV infections in pediatric patients after allogeneic stem cell transplantation - Report - MDSpire
Advertisement
Case Report: BKV-specific T cells: a fast, safe and potentially effective treatment option for refractory BKV infections in pediatric patients after allogeneic stem cell transplantation
Clinical Report: The Role of BKV-Specific T Cells in Pediatric Patients
Overview
This case series evaluates the use of BKV-specific T cells as a treatment for refractory BK virus infections in pediatric patients post-allogeneic stem cell transplantation. The findings suggest that this approach is feasible and safe, with some patients experiencing a reduction in viral load.
Background
BK virus reactivation is a significant concern following allogeneic stem cell transplantation, often leading to complications such as nephropathy and hemorrhagic cystitis. Current treatment options are limited and primarily supportive, highlighting the need for innovative therapies. The adoptive transfer of virus-specific T cells has shown promise in treating other viral infections, making it a potential therapeutic strategy for BKV infections.
Data Highlights
Patient
Viral Load Change
BKV-Specific T Cells Detected
Patient 1
Decrease
Yes
Patient 2
Decrease
Yes
Patient 3
No Change
No
Patient 4
Minimal Response
No
Key Findings
Three out of four patients showed a decrease in BKV viral load after T-cell transfer.
In vivo expansion of BKV-specific T cells was measurable in these patients.
One patient with significant immunosuppression had minimal viral response and no detectable BKV-specific T cells post-infusion.
The treatment was well tolerated with no infusion-related adverse effects reported.
No severe de novo graft-versus-host disease was observed in any patient.
Clinical Implications
The use of BKV-specific T cells may provide a novel therapeutic option for pediatric patients with refractory BKV infections following stem cell transplantation. Clinicians should consider the timing of administration and the management of immunosuppression to potentially enhance treatment efficacy.
Conclusion
This case series supports the feasibility and safety of BKV-specific T cell therapy in managing refractory BKV infections, warranting further investigation to establish its effectiveness.
In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...
Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...
